3:35 PM
 | 
Jul 03, 2014
 |  BC Extra  |  Top Story

Regado slips on Revolixys trial halt

Regado Biosciences Inc. (NASDAQ:RGDO) fell $3.92 (58%) to $2.84 on Thursday after announcing late Wednesday that it halted enrollment in the Phase III REGULATE-PCI trial with its Revolixys Kit (formerly REG1) to treat acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >